Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study

Parkinson plus diseases, comprising mainly progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are rare neurodegenerative conditions. We designed a double-blind randomized placebo-controlled trial of riluzole as a potential disease-modifying agent in Parkinson plus disorders (NNIP...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Bensimon, Gilbert, Ludolph, Albert, Agid, Yves, Vidailhet, Marie, Payan, Christine, Leigh, P. Nigel
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2009
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2638696/
https://ncbi.nlm.nih.gov/pubmed/19029129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/brain/awn291
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller